CNX Therapeutics

Privately held: no public share price · United Kingdom

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Nabiximols(Sativex)
Phase 3
Cannabinoid CB1/CB2 receptors (agonist)Botanical
Multiple Sclerosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.